Darnitsa digitalizes its pharmacovigilance system to meet the requirements of foreign regulators 3 min read
Darnitsa pharmaceutical company is developing its pharmacovigilance system, its digitalization allowing the company to meet the modern requirements of foreign regulators, said Head of the Department for Regulatory Issues of Darnitsa Oleksandr Torhun.
‘The modern system of pharmacovigilance will allow Darnitsa in the long term to successfully meet the demands of those regulators that require more extensive data for registration dossiers. In fact, we are proactive in this case. After all, the capabilities of the new system are much wider than the classic format of pharmacovigilance,” the press service of the company quotes Torhun.
Share this article
Share this article
ResearchAndMarkets.com s offering.
The global ibuprofen market is projected to reach US$7.54 billion in 2024, progressing at a CAGR of 2.47%, over the period 2020-2024. The factors such as upsurge in healthcare expenditure, rising prevalence of arthritis, surging incidence of cancer cases, expanding urbanization and escalating sales of analgesic drugs would drive the growth of the market. However, the market growth would be challenged by adverse side effects and increase in the price of raw materials. A few notable trends include mounting e-commerce penetration, upswing in sports injuries, surging occurrence of chronic disorders and increasing public awareness.